drugset / Trial / NCT03945812

Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer

NCT03945812

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to assess the impact of using Platelet-Rich Plasma (PRP) vs. Granulocyte Colony-Stimulating Factor (GCSF) vs. placebo on the outcomes of frozen embryo transfer (FET) in terms of clinical pregnancy rates. It will also assess their effect on chemical pregnancy rate, implantation rate, delivery outcomes, and endometrial parameters. The main questions it aims to answer are: Do the clinical pregnancy rates differ upon using PRP vs. GCSF vs. placebo during FET? What are the effects of PRP vs. GCSF vs. placebo during FET on chemical pregnancy rate, implantation rate, delivery outcomes, and endometrial parameters? Researchers will compare the effect of administration of PRP vs. GCSF vs. placebo during FET on pregnancy outcomes. Participants will be randomized to receive the study intervention seven days before embryo transfer: 1.0 ml of either PRP (prepared in-house), GCSF (Filgrastim, 300 mcg/1.0 mL), or 0.9% saline (placebo). The intervention will be administered by slow infusion into the uterine cavity with an intrauterine insemination catheter.

Timeline

Start
2019-06-01
Primary completion
2022-03-31
Completion
2023-03-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator filgrastim Protein / enzyme biologic 300 ug Other

Indications